T. Rowe Price Investment Management Inc. Has $5.08 Million Stock Holdings in Applied Therapeutics Inc. $APLT

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Applied Therapeutics by 91.5%, acquiring 4,959,670 shares during the first quarter, bringing its total holdings to approximately 10.38 million shares.
• Applied Therapeutics reported an EPS of ($0.15) for the last quarter, surpassing analyst expectations by $0.02, while analysts anticipate an annual EPS of ($0.65).
• The current market capitalization of Applied Therapeutics is approximately $73.73 million, with analysts giving it an average rating of "Moderate Buy" and a target price of $6.10.

T. Rowe Price Investment Management Inc. raised its stake in shares of Applied Therapeutics Inc. (NASDAQ:APLT - Free Report) by 91.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 10,380,590 shares of the company's stock after purchasing an additional 4,959,670 shares during the quarter. T. Rowe Price Investment Management Inc. owned 7.33% of Applied Therapeutics worth $5,076,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Legal & General Group Plc grew its position in Applied Therapeutics by 293.9% during the fourth quarter. Legal & General Group Plc now owns 84,018 shares of the company's stock worth $72,000 after buying an additional 62,686 shares in the last quarter. XTX Topco Ltd lifted its position in shares of Applied Therapeutics by 178.0% in the 4th quarter. XTX Topco Ltd now owns 173,568 shares of the company's stock worth $149,000 after acquiring an additional 111,128 shares during the period. Marshall Wace LLP lifted its position in shares of Applied Therapeutics by 144.8% in the 4th quarter. Marshall Wace LLP now owns 1,307,381 shares of the company's stock worth $1,124,000 after acquiring an additional 773,377 shares during the period. Dark Forest Capital Management LP grew its holdings in shares of Applied Therapeutics by 54.5% during the 4th quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company's stock worth $46,000 after purchasing an additional 18,949 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Applied Therapeutics during the fourth quarter valued at approximately $49,000. Institutional investors and hedge funds own 98.31% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on APLT shares. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $1.50 target price on shares of Applied Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen upgraded shares of Applied Therapeutics to a "sell" rating in a research note on Saturday, July 26th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Applied Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $6.10.

Applied Therapeutics Price Performance

Shares of APLT traded down $0.02 during trading hours on Friday, hitting $0.49. The stock had a trading volume of 488,401 shares, compared to its average volume of 812,814. The stock has a market capitalization of $70.95 million, a price-to-earnings ratio of -1.09 and a beta of 1.97. The company's fifty day moving average is $0.44 and its two-hundred day moving average is $0.44. Applied Therapeutics Inc. has a 52 week low of $0.30 and a 52 week high of $10.62.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02. Equities analysts predict that Applied Therapeutics Inc. will post -0.65 EPS for the current fiscal year.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.